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Abstract 
Objectives. Several studies have reported a decline in incidence of dementia which may have large implications for 
the projected burden of disease, and provide important guidance to preventive efforts. However, reports are 
conflicting or inconclusive with regard to the impact of gender and education with underlying causes of a presumed 
declining trend remaining largely unidentified. 
Methods. The Alzheimer Cohorts Consortium aggregates data from nine international population-based cohorts to 
determine changes in the incidence of dementia since 1990. We will employ Poisson regression models to calculate 
incidence rates in each cohort and Cox proportional hazard regression to compare 5-year cumulative hazards across 
study-specific epochs. Finally, we will meta-analyse changes per decade across cohorts, and repeat all analysis 
stratified by sex, education and APOE genotype.  
Results. In all cohorts combined there is data on almost 69,000 people at risk of dementia with the range of follow-
up years between 2 and 27.  The average age at baseline is similar across cohorts ranging between 72 and 77.   
Discussion. Uniting a wide range of disease-specific and methodological expertise in research teams, the first 
analyses within the Alzheimer Cohorts Consortium are underway to tackle outstanding challenges in the assessment 
of time-trends in dementia occurrence.   
 
 
Keyword. Alzheimer disease, Cohort Analysis, Epidemiology, Consortium  
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Introduction 
It is estimated that approximately 47 million people are currently living with dementia, making it a leading cause of 
dependence and disability worldwide [1]. Because of a rapidly aging population, this number is predicted to have 
nearly doubled by 2040 [2]. Consequently the social and economic burdens of dementia are expected to substantially 
increase [3]. Yet, the projected burden of disease could be significantly lower if improvements in life conditions and 
health care over the last decades have had a beneficial effect on reducing risk of dementia. Indeed, recent studies in 
North America and Europe have reported a decline in the incidence of dementia over the last 20 years, up to 20% 
reduction per decade [4-8]. However, the underlying causes have not been determined, and discrepancies in 
described trends between sexes, and across different ethnicities and levels of education warrant further exploration 
[9, 10].  
 
Valid assessment of time trends in the incidence of a disease calls for careful monitoring of it within the general 
population, in a consistent manner over a prolonged period of time. Population-based cohort studies are generally 
designed to establish determinants of disease, using consistent methodology throughout the course of data 
collection. The wide range of routinely collected data within these studies allows for exploration of effect modifiers 
(e.g. genotype or sex), as well as various potential underlying causes, such as changes in cardiovascular risk 
management, comorbidity (e.g. stroke), and level of education. Worldwide, however, only a limited number of 
studies exist, that are carried out in unselected populations and provide the infrastructure and decade-long follow-up 
duration necessary to determine trends in dementia incidence. Power and precision of these individual studies are 
not always sufficient to answer the research questions outlined above. We therefore aim to jointly analyse available 
long-term population-based data seeking confirmation for any time trends in dementia occurrence, and importantly 
identify determinants of such trends. The results will have important implications for informing public health policy 
focused on dementia reduction.  
 
Material and Methods 
The Alzheimer Cohorts Consortium  
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The Alzheimer Cohorts Consortium is a collaboration of nine prospective cohorts studies from the United States and 
Europe including: the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study, the Atherosclerosis Risk in 
Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Cognitive Function and Ageing Studies 
(CFAS), the Framingham Heart Study (FHS), the Gothenburg population studies, the Personnes Agées QUID 
(PAQUID) study, the Rotterdam Study (RS), and the Three-City Study (3C). All cohorts are population-based and 
comprise of prospectively collected data on dementia (and in most studies information on clinical subtypes), in 
addition to genotyping, and extensive (cardiovascular) phenotyping.  
 
Description of Cohorts 
A summary of the key characteristics of each cohort are presented in Table 1. Across the cohorts there are more 
than 70,000 individuals of whom around 6,300 have developed dementia to date. Briefly, the AGES-Reykjavik 
Study represents a sample drawn from the population-based Reykjavik Study [11]. The original Reykjavik Study 
comprised a random sample of 30,795 men and women born between 1907 and 1935 and living in Reykjavik in 
1967. Between 1967 and 1996, six examinations were conducted in six sub-cohorts, and 5,764 survivors of the 
original cohort were re-examined for the AGES-Reykjavik study between 2002 and 2006. The ARIC study is a 
population-based prospective cohort study of cardiovascular disease and its risk factors [12]. Chosen by probability 
sampling from four U.S. communities including Winston-Salem (NC), Jackson (MS), Minneapolis (MN), and 
Baltimore (MD), the study included 15,792 individuals aged 45–64 years at study baseline in 1987–1989. 
Participants completed four clinic examinations, conducted three years apart, up till 1998, and undergo annual 
follow-up for clinical events. Between 2011 and 2013, all surviving ARIC participants were 
invited to a 5th visit (ARIC Neurocognitive Study (ARIC-NCS), when a comprehensive dementia assessment was 
performed. The CHS is a population-based cohort study of risk factors for cardiovascular disease in adults aged 65 
years and older, recruited in 1989–1990 from random samples of the Medicare lists in four U.S. field centers, 
namely Sacramento (CA), Hagerstown (MD), Winston-Salem (NC), and Pittsburgh (PA) [13] The original 
predominantly white cohort of 5,888 persons was expanded by enrolment of 687 African-Americans in 1992–1993. 
Participants completed standardized clinical examinations and questionnaires at study baseline and at annual follow-
up visits until 1999. Ongoing follow-up for clinical events occurs by phone every 6 months since. The CFAS 
comprise two population-based studies in three sites (Cambridgeshire, Newcastle and Nottingham), conducted 20 
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years apart in the UK.[5] The sample includes individuals aged 65 years and over regardless of residential status (i.e. 
persons living in the community as well as institutions). The first study recruited in 1989-1994 (CFAS I, N=7,635). 
A comparison study was initiated two decades later, between 2008 and 2011 (CFAS II, N=7,796). Participants have 
been followed biennially. The FHS began in 1948 with the recruitment of an original cohort of 5,209 men and 
women who were aged 28 to 62 at study entry [14]. In 1971, a second generation of study participants, including 
5,124 children and spouses of children of the original cohort were enrolled [15]. Enrolment of the third generation 
cohort of 4,095 children of offspring cohort participants began in 2002 [16]. Clinic follow-up examinations take 
place approximately every two, four, and six years for the Original, Offspring, and Third Generation cohorts, 
respectively. In addition, the cohorts are under continuous surveillance for disease endpoints, such as myocardial 
infarction, stroke, and dementia. The Gothenburg population studies consist of data from four studies which 
recruited individuals representative of the Swedish population [17]. These include Kvinnoundersökningen (KVUS), 
a study of 1,462 women aged 38-60 who have been followed since 1968; the H70 study, which includes 
representative samples of 70-year-olds born 1906-1907 (N=414), recruited 1976-1977, and followed until death, and 
1930 (N=522), recruited 2000-2001 and followed until now, the H85 study, which includes samples of 85-year-olds 
born 1901-1902 (N=494), first examined in 1986 and followed until death, and 1923-1924 (N=571), first examined 
in 2008-2009 and followed until age 90; and the 95-plus study that started in 1996 and by 2012 had recruited a total 
of 950 individuals. The PAQUID cohort is a population-based study in the southwest of France of 3,777 individuals 
aged 65 years or older recruited in 1988 [18]. There have been nine waves of data collection at 1, 3, 5, 8, 10, 13, 15, 
17, 20, 23, 25, and 27 years after the baseline assessment. The RS is a prospective population-based cohort study 
comprising 14,926 subjects aged 45 years or older [19]. Baseline data of 7,983 participants were collected between 
1990 and 1993, with subsequent cohort expansions in 2000 (3,011 individuals) and 2006 (3,236 individuals). 
Participants have been examined once every 4 years. In addition, the entire cohort is continuously under surveillance 
for disease outcomes through linkage of electronic medical records with the study database. The 3C is a longitudinal 
population-based study of the relation between vascular diseases and dementia in persons aged 65 years and older 
[20]. Between 1999 and 2001, a total of 9,294 non-institutionalized persons were recruited from the electoral rolls of 
three French cities: Bordeaux (South-West), Dijon (North-East) and Montpellier (South-East). Participants have 
been re-examined every 2 years.   
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Ethics 
All participating studies have ethical approval, and all subjects (or their nominated representative) provided written 
informed consent.  
 
Dementia Assessment 
The primary outcome is all-cause dementia and this is assessed in all cohorts (Table 1). The secondary outcome is 
diagnoses of Alzheimer’s disease (AD), the most common clinical subtype. Methods for dementia diagnosis varied 
between cohorts, but re consistently applied in each cohort throughout the study period. An exception is CHS, in 
which participants are re-examined more frequently from 2002 onwards (i.e. annually) compared to before diagnosis 
of dementia and is based on change in cognition and function from previous visits. 
 
Defining epochs 
One option for assessing trend over time is to define units of time based on the same calendar years across cohorts. 
This method makes it easy to combine results across cohorts, but ignores the fact that each study has its own pattern 
of examination cycles and therefore risks bringing in more biases based on study design. To avoid this we choose to 
define units of time, or epochs, specific to each study based on each interview wave. This allows us to take full 
advantage of all available data in each study, maximize the person-years available and also, by using the median 
time since beginning of first epoch (as described in more detail below in the statistical analysis section), we can 
compare trends over the years across all the cohorts. Requirements for defining an epoch are: (1) start at or close to 
an examination cycle, (2) non-overlapping with previous or subsequent epoch, and (3) at least 5 years in length. 
Participants need to be 60 years or over, and free of dementia at the start of the epoch to be included. All cohorts 
have follow-up for at least two epochs, except for AGES, in which only a baseline epoch has sufficient follow-up. 
 
Statistical Analysis  
All analyses are currently being performed in individual cohorts and results will be meta-analysed when appropriate. 
Demographic characteristics of each cohort are summarized using means with standard deviation (SD) for 
continuous measures and frequencies for categorical measures. The calendar time-window of the present analyses is 
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restricted to 1990-2015 to allow for assessment of incidence rates and time trends across the same time-period 
across cohorts. 
 
Five-year incidence rates (IRs) with 95% confidence intervals (CI) are being calculated using age-adjusted Poisson 
regression models. Groups are first stratified by 5-year age-groups and then additionally by sex. IRs are reported for 
the middle age within each age group, e.g. 62.5 for the [60-65] age group, 67.5 for the [65-70] age group, etcetera. A 
participant is included in a particular age group if they were dementia-free at start of the age group category. Since 
all the cohorts have repeated visits with participants, when data was available, a single person could contribute to 
IRs of multiple age groups. To account for this, we employ robust sandwich estimators to calculate the 95%CI 
around the IRs.    
 
Five-year cumulative hazards and hazard ratios are assessed individually in each cohort and not combined across 
studies because of differing timing of examinations. Non-overlapping epochs are defined based on examination 
cycles and are specific to each cohort. Five-year cumulative hazard and hazard ratios (HRs) are calculated using a 
Cox proportional hazard regression model and adjusted for age and sex in non-stratified models using a robust 
sandwich estimator for covariance structure [21]. Participants who did not experience a dementia diagnosis are 
censored at the last date they were known to be free of dementia, or 5 years after the beginning of the epoch, 
whichever was sooner. Hazard ratios are being computed for each epoch as compared to the first epoch followed by 
trend per decade. We do this by assigning to each epoch an index value equal to median time in years since the 
beginning of the first epoch. For example, if epoch 1 was 1995-1999 and epoch 2 was 2000-2005 then the index 
variable would be 2.5 and 7.5 respectively. The index variable is then used in the Cox proportional hazard regression 
to assess a linear change in hazard of dementia over the epochs or linear trend. To ensure the analyses are identical 
across cohorts, statistical code using both SPSS and SAS was developed and tested using the Rotterdam Study 
dataset to ensure results matched between statistical software programs and then provided to each cohort for 
analyses. All analyses are currently being performed using either SPSS version 23.0 (IBM Corp, Armonk, NY, 
USA) or SAS 9.4 (Cary, North Carolina).   
 
Results 
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Descriptions of all cohorts are summarized in Table 1.  In all cohorts combined there is data on almost 69,000 
people at risk of dementia with the range of follow-up years between 2 and 27.  The average age at baseline is 
similar across cohorts ranging between 72 and 77 (Table 2).  Each cohort is made up of >50% females, ranging 
from 56.8% in FHS to 76.3% in the Gothenburg studies (Table 2).  All cohorts collect information on incident 
dementia and all but one cohort (CFAS I/II) also collecting information on incident AD. 
 
Discussion 
Several of the cohorts within the Alzheimer Cohorts Consortium have previously published data on time trends in 
the prevalence and incidence of dementia [4, 5, 7, 8]. In this collaboration, we aim to reproduce these findings using 
consistent analytical techniques, and harmonise results from the individual cohort studies to identify underlying 
trends and investigate subgroups of interest (e.g. stratification by gender) and effect modifiers. The close 
collaboration between cohorts in the consortium, along with the high-quality study design and data collection 
methods facilitate these analyses of incidence trends over the past three decades.  
 
Cohort enrolment, resampling, and survival bias 
Most cohorts contributing data to these analyses use a closed-cohort design with single enrolment, while two of the 
cohorts, FHS and the Rotterdam Study, are expanded during the study period, including additional individuals from 
the source population. Single enrolment in closed cohorts will limit the number of comparable individuals within the 
same age range, as the cohort on average becomes older over time. We intend to utilize the full potential of this 
collaboration by including all available data, i.e. expansion cohorts as well as the originally defined cohorts. On a 
participant level, we allow a single participant to be included in multiple epochs as long as they are free of dementia 
at the start of the epoch. This can lead to underestimation of the standard error and thus we utilize robust standard 
error estimates. Restricting non-demented participants to only a single epoch, such as the epoch of their first 
examination, would deplete the number of participants susceptible to dementia over time. This would mean that 
individuals at high risk would be underrepresented at later time points. Such selection bias could result in 
underestimation of the incidence rates and cumulative hazards in more recent years. Conversely, mortality rates have 
dropped substantially over the past decades, and the increase in life-expectancy renders more people susceptible to 
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dementia these days than in earlier years. This survival bias may cause underestimation of a declining trend in the 
incidence of dementia. 
 
All-cause dementia as a primary outcome measure 
Distinguishing clinical AD from other dementia subtypes such as vascular dementia or dementia with Lewy bodies 
has proven challenging in light of the multiple pathologies co-occurring with increased age in the majority of cases 
with dementia [22]. This is particularly troubling as the incidence of dementia increases steeply with age, with the 
vast majority of dementia cases occurring after 70 years of age. Studies of dementia and sporadic AD focused on 
older aged samples consequently recruit individuals in whom a large number of factors (e.g. neurodegenerative and 
vascular) contribute to cognitive decline and dementia, hampering accurate diagnosis of dementia subtypes. Not 
only does this burden etiological research, it could also contribute to heterogeneity in dementia diagnoses between 
cohorts. In addition, diagnosis of all-cause dementia is less susceptible to changes in clinical subtyping of dementia 
that may have occurred over time. For these reasons, the focus of the analysis is on all-cause dementia, which can be 
more reliably defined across cohorts. The wide age range of the unselected populations guarantees generalizability 
to understudied elderly individuals, and reflects the full spectrum of the dementia burden in the population.  
 
Dementia occurrence across cohorts 
Despite many similarities in design and data collection between the cohorts in this collaboration, there are also 
factors that may lead to differences in baseline incidence rates across the different cohorts.  These include 
underlying population traits (e.g. access to health care, socioeconomic status, genetic make-up, and lifestyle), and 
variations in methodology (e.g. re-examination interval, continuous surveillance methods). For the most part these 
are likely to remain constant over the course of the study period, and although contributing to differences in baseline 
incidence, arguably less likely to influence within study trends. Differences in risk of mortality across cohorts, 
however, may differentially affect the results, because of survival bias, as described above. In addition, differences 
in the diagnosis of dementia across cohorts and region-specific changes in the clinical assessment of dementia over 
time pose a challenge to trend analysis. Last, all cohorts are embedded within the general population, but cannot 
completely avoid variation in sampling strategies and inclusion rates. Moreover, strategies for follow-up and disease 
surveillance vary, potentially affecting attrition or diagnostic sensitivity, which may hamper absolute risk estimates 
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in particular. Variation may, in part, may be addressed by accounting for genetic heterogeneity, further stratification 
when sample size allows (e.g. for educational attainment, vascular disease burden), or use of more advanced 
statistical methods, such as illness-death modelling to deal with death occurring during the inter-examination 
interval. 
 
Within the Alzheimer Cohorts Consortium nine prospective population-based cohort studies leverage 
conscientiously collected data over a 25-year period with the aim to determine trends in the incidence of dementia, 
and to unravel underlying causes. Uniting a wide range of disease-specific and methodological expertise in research 
teams within and beyond these cohorts, the first analyses within the Alzheimer Cohorts Consortium are underway to 
tackle outstanding challenges in the assessment of time-trends in dementia occurrence.   
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Table 1. Description of the cohorts included in the Alzheimer Cohorts Consortium 
Study 
AGES-
Reykjavik 
ARIC 
NCS 
CFAS I/II CHS 
Framingham 
Heart Study 
Gothenburg 
Studies 
PAQUID 
Rotterdam 
Study 
Three-City 
Study 
Country Iceland USA UK USA USA Sweden France Netherlands France 
Study baseline 2002 
2011-
2013 
1991 / 
2008 
1991 1990 1990 1988 1990 1999 
Family-based  no No no no yes no no no no 
Study sites 1 4 3 / 3 4 1 1 1 1 3 
Dementia follow-
up,  y 
14 5a 2 / 2 18 25 25 27 25 16 
Diagnosis of 
dementia 
DSM-IV DSM-V DSM-IIIR DSM-IV DSM-IV DSM-IIIR DSM-IIIR DSM-IIIR DSM-IV 
Diagnosis of AD 
NINCDS-
ADRDA 
NIA-AA NA 
NINCDS-
ADRDA 
NINCDS-
ADRDA 
NINCDS-
ADRDA 
NINCDS-
ADRDA 
NINCDS-
ADRDA 
NINCDS-
ADRDA 
Note. AGES=Age, Gene/Environment Susceptibility, ARIC=Atherosclerosis Risk in Communities, CFAS=Cognitive Function and Ageing Studies, 
CHS=Cardiovascular Health Study, PAQUID=Personnes Agées QUID, AD=Alzheimer’s disease, NA=Not Available 
a Efforts to work-up recent incident dementia cases are ongoing as of January 2017 
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Table 2. Demographics of the cohorts included in the Alzheimer Cohorts Consortium 
Study 
AGES-
Reykjavik 
ARIC 
NCS 
CFAS I/II CHS 
Framingham 
Heart Study 
Gothenburg 
Studies 
PAQUID 
Rotterdam 
Study 
Three-City 
Study 
At risk of 
dementia 
5,722 6538 
7,635 / 
7,762 
2,798 8,586 3,024 2,997 11,044 8,250 
Mean age, y 77.0 75.8 75.0 / 76.4 74.7 72.1 77.3 75.3 72.0 74.0 
Women, % 57.7% 58.8% 
61.6% / 
56.1% 
59.1% 56.8% 76.3% 58.0% 58.5% 61.3% 
Caucasian 
ethnicity, % 
100% 76.1% 
99.1% / 
97.2% 
89.5% 100% 100% NCb 98.0% 100% 
Incident dementiaa 250 344 250 / 250 680 800 700 940 1,400 950 
Incident ADa 150 72 N/A 590 510 300 730 1,100 650 
Note. AGES = Age, Gene/Environment Susceptibility, ARIC = Atherosclerosis Risk in Communities, CFAS = Cognitive Function and Ageing Studies, CHS = 
Cardiovascular Health Study, PAQUID = Personnes Agées QUID, AD=Alzheimer’s disease, y=years 
a Approximation of total number of individuals with dementia per cohort at time of press,  b Not collected 
